Attached files
| file | filename |
|---|---|
| EX-23.2 - EXHIBIT 23.2 - GENEREX BIOTECHNOLOGY CORP | ex23_2.htm |
| EX-21 - EXHIBIT 21 - GENEREX BIOTECHNOLOGY CORP | ex21.htm |
| S-1 - FORM S-1 - GENEREX BIOTECHNOLOGY CORP | gnbt120619forms1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the use in this Pre-Effective Registration Statement on Form S-1 to be filed on December 12, 2019 of our report dated November 12, 2019, related to the consolidated financial statements of Generex Biotechnology Corporation and Subsidiaries as of July 31, 2019 and for the fiscal year then ended, which appears in such Pre-Effective Registration Statement of Generex Biotechnology Corporation and Subsidiaries for the fiscal year ended July 31, 2019. The report for Generex Biotechnology Corporation and Subsidiaries includes an explanatory paragraph about the existence of substantial doubt about its ability to continue as a going concern. We also consent to the reference to our Firm under the caption “Experts” in such Pre-Effective Registration Statement.
/s/ Mazars USA LLP
Edison, New Jersey
December 12, 2019